Fig. 3From: Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective studyIndividual Responder Change in HBsAg and ALT (FAS). ALT, alanine aminotransferase; FAS, full analysis set; HBsAg, hepatitis B surface antigen; W, weeksBack to article page